ResMed's Q4 Results: Analysts Say Uncertain Market Dynamics

ResMed Inc (NYSE: RMD) posted Q4 adjusted EPS of $1.60, up from $1.49 a year ago, missing the consensus of $1.67.

Related Keywords

, David Saxon , Resmed Inc , Matthew Mishan , Margaret Kaczor , Elizabeth Bui , Macauley Kilbane , William Blair , Brett Fishbin , Mike Matson , Joseph Conway , Philips ,